References
- Faber O K, Binder C. C‐peptide response to glucagon. A test for the residual β‐cell function in diabetes mellitus. Diabetes 1977; 26: 605–10
- Madsbad S, Krarup T, McNair P, Christiansen C, Faber O K, Transböl I, Binder C. Practical clinical value of the C‐peptide response to glucagon in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153–6
- Hoekstra J BL, Van Rijn H JM, Thijssen J HH, Erkelens D W. C‐peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin. Diabetes Care 1982; 5: 585–91
- Mirel R D, Ginsberg‐Fellner F, Horwitz D L, Rayfield E J. C‐peptide reserve in insulin‐dependent diabetes. Comparative responses to glucose, glucagon and tolbutamide. Diabetologia 1980; 19: 183–8
- Rendell M. C‐peptide levels as a criterion in treatment of maturity‐onset diabetes. J Clin Endocrinol Metab 1983; 57: 1198–206
- Beischer W, Kerner W, Raptis S, Keller L, Beischer B, Pfeiffer E F. Insulin therapy in relation to circulating C‐peptide levels. Diabetes 1978; 27(Suppl. 1)161–9
- Hendriksen C, Faber O K, Drejer J, Binder C. Prevalence of residual β‐cell function in insulin‐treated diabetics evaluated by the plasma C‐peptide response to intravenous glucagon. Diabetologia 1977; 13: 615–9
- Oakley N W, Harrigan P, Kissebah A H, Kissin E A, Adams P W. Factors affecting insulin response to glucagon in man. Metabolism 1972; 21: 1001–7
- Welborn T A, Carcia‐Webb P, Bonser A M. Basal C‐peptide in the discrimination of type I from type II diabetes. Diabetes Care 1981; 4: 616–9
- Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75–85